Electronic Resource
Springer
Digestive diseases and sciences
12 (1967), S. 973-982
ISSN:
1573-2568
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Summary A standard anticholinergic drug was compared to a sustained-release preparation of the same agent. Two 6-hr. doses of glycopyrrolate were equivalent to one dose of a glycopyrrolate Extentab in suppressing basal gastric secretion in subjects with acid-peptic disease. The effect of subject selection on the trial was tested by preselecting patients on the basis of gastric secretory capacity, subsequently measuring basal gastric secretion, and reassessing drug results against basal secretion. The subjects fell into basal hypersecreting and normosecreting groups. In the latter group, basal secretion and drug-inhibited secretion results were close and threatened the validity of the trial. Neither the diagnosis of acid-peptic disease nor the demonstration of increased gastric secretory capacity is sufficient to qualify a subject for an anti-cholinergic drug trial, since his basal secretion may still be low enough to be confused with a satisfactory drug response. Anticholinergic drugs should be tested in subjects with demonstrated basal hypersecretion to avoid this error. Twelve-hour daytime basal gastric secretion data revealed: (1) unreliability of the initial hours; (2) variation from hour to hour; and (3) wide fluctuations over periods of several hours which were unexplained. To avoid errors from these factors, anticholinergic drug trials should be made over prolonged periods and should include identical control periods in a crossover design.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF02233255
Permalink
| Library |
Location |
Call Number |
Volume/Issue/Year |
Availability |
